2型糖尿病白蛋白尿相关的肠道微生物特征与代谢物鉴定
基于瑞典SCAPIS研究中752例2型糖尿病患者的粪便宏基因组和血浆代谢组数据,分析了1002种肠道微生物与1308种血浆代谢物和白蛋白尿的关联。鉴定出3种与白蛋白尿相关的菌种,其中2种在独立糖尿病前期人群(n=3423)中重复验证,并发现36种注释代谢物与这3种菌相关。功能映射提示这些菌种可能通过调节咪唑丙酸和葫芦巴碱代谢参与白蛋白尿进展。
要点
- 3种肠道菌种(Sellimonas intestinalis、Eggerthellales sp.、Ellagibacter isourolithinifaciens)与2型糖尿病患者的白蛋白尿相关。
- 其中2种菌种在独立糖尿病前期人群(n=3423)中得到重复验证。
- 36种血浆代谢物与上述3种白蛋白尿特征菌种相关,功能映射提示咪唑丙酸和葫芦巴碱代谢途径可能参与。
核心结论
- 肠道微生物物种和血浆代谢物与2型糖尿病患者的白蛋白尿存在关联,提示微生物-代谢物轴可能影响白蛋白尿进展。
研究设计与样本
- 研究纳入瑞典SCAPIS研究中752例2型糖尿病患者,采用深度鸟枪法宏基因组测序分析粪便样本中1002种肠道微生物的相对丰度,并用质谱法分析血浆中1308种代谢物,以探讨其与白蛋白尿的关联。
- 关键菌种在SCAPIS独立糖尿病前期人群(n=3423)中进行重复验证。
主要发现
- 鉴定出3种与白蛋白尿相关的菌种:Sellimonas intestinalis、Eggerthellales sp.、Ellagibacter isourolithinifaciens。
- 其中2种菌种在独立糖尿病前期人群(n=3423)中重复验证。
- 共36种注释代谢物与这3种白蛋白尿特征菌种相关。
- 功能映射提示这些特征菌种可能参与调节咪唑丙酸和葫芦巴碱代谢,这两种代谢物此前被报道与白蛋白尿进展有关。
临床怎么用
- 在2型糖尿病管理中,可关注与白蛋白尿相关的特定肠道菌种及代谢物(如咪唑丙酸、葫芦巴碱)作为潜在生物标志物或干预靶点,但需进一步研究验证。
局限性
- 原文未明确报告局限性,但研究为观察性设计,无法确定因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Type 2 diabetes is a growing global concern with serious complications, including kidney damage and cardiovascular morbidity and mortality. Monitoring albuminuria, which is associated with these complications, is crucial in optimal diabetes management. Gut microbiota composition has been suggested to impact albuminuria, but large studies with granular data are lacking. METHODS: We investigated the relationship between 1002 gut microbial species, 1308 plasma metabolites, and albuminuria in 752 participants with type 2 diabetes from the Swedish CArdioPulmonary BioImage Study (SCAPIS). To determine the relative abundance of species, we employed deep shotgun metagenomic sequencing of fecal samples. Plasma metabolites were analyzed using mass spectrometry-based methods. RESULTS: We identified 3 species that were associated with albuminuria, including Sellimonas intestinalis, Eggerthellales sp., and Ellagibacter isourolithinifaciens. Two of these species were replicated in an independent prediabetic population (n = 3423) in SCAPIS. In total, 36 annotated metabolites were associated with the 3 albuminuria-signature species. Functional mapping of the signature species suggests a role in the regulation of the metabolites of imidazole propionate and trigonelline, which have previously been reported to play roles in the progression of albuminuria. CONCLUSION: These findings provide additional evidence of the potential impact of microbial species and contribute to our understanding of the complex relationship between the gut microbiome, plasma metabolites, and albuminuria in individuals with diabetes.
引用
- Lin YT, Sayols-Baixeras S, Graells T, et al. Identification of Gut Microbiome Signatures and Metabolites Associated With Albuminuria in Type 2 Diabetes. J Clin Endocrinol Metab. 2026. PMID: 40810199. doi:10.1210/clinem/dgaf453
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。